AYTU BioPharma, Inc. logo

AYTU BioPharma, Inc. (AYTU) Q1 2025 Earnings

AYTU·Reported May 14, 2025·After market close

AYTU BioPharma, Inc. reported Q1 2025 revenue of $18.5M (+2.6% YoY), missed analyst consensus of $18.8M by $380.5K. Diluted EPS came in at $0.20, beat the $-0.17 consensus by $0.37.

Revenue
$18.5Mmissed by $380.5K
Consensus: $18.8M
Diluted EPS
$0.20beat by $0.37
Consensus: $-0.17
SEC

SEC Filings

Earnings release8-K not filed yet
Quarterly report10-Q · 0001437749-25-016833

Financial Snapshot

Trailing eight quarters through Q1 2025

View all metrics

Revenue

View metric

Net Income

View metric

Operating Cash Flow

View metric

EPS (Diluted)

View metric

Q1 2025 Earnings FAQ

Common questions about AYTU BioPharma, Inc.'s Q1 2025 earnings report.

AYTU BioPharma, Inc. (AYTU) reported Q1 2025 earnings on May 14, 2025 after market close.

AYTU BioPharma, Inc. reported revenue of $18.5M and diluted EPS of $0.20 for Q1 2025.

Revenue missed the consensus estimate of $18.8M by $380.5K. EPS beat the consensus estimate of $-0.17 by $0.37.

Compared to the same quarter a year prior, revenue grew 2.6% from $18.0M a year earlier.

You can read the 10-Q periodic report (0001437749-25-016833) directly on SEC EDGAR. The filing index links above go to sec.gov.